MicroRNA在直肠癌新辅助治疗疗效预测中的作用

doi:10.3760/cma.j.issn.1004-4221.2020.03.016

Abstract
Figure/Table
References(29)
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Neoadjuvant chemoradiotherapy (NCRT) has become the standard treatment for patients with locally advanced rectal cancer (LARC). However,the response to NCRT varies among LARC patients and a subset of patients show resistance to NCRT. NCRT may delay the timing of surgery and even reduce the overall survival. Therefore,it is of significance to identify biomarkers for predicting the clinical efficacy of NCRT, screen patients who are resistant to NCRT and perform surgery as early as possible, eventually establishing an individualized therapeutic strategy. MicroRNAs are a class of small non-coding RNAs that post-transcriptionally regulate gene expression, which areinvolved in multiple signaling pathways and DNA damage repair process and affect the radiosensitivity of rectal cancer cells. Many recent studies have evaluated the role of microRNA in predicting the response to NCRT. The purpose of this article is to review the research progress and validate the role of microRNA in predicting the clinical efficacy of NCRT for rectal cancer.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Yao Wenyan
	Peng Qiliang
	Zhu Yaqun
	Tian Ye

Key words： Rectal neoplasm/neoadjuvant chemoradiotherapy MicroRNA Predict

Received: 07 October 2018

Corresponding Authors: Zhu Yaqun,Email:szzhuyaqun@sina.com

Cite this article:

Yao Wenyan,Peng Qiliang,Zhu Yaqun et al. Role of microRNA in predictingclinical efficacy of neoadjuvant chemoradiotherapy for rectal cancer[J]. Chinese Journal of Radiation Oncology, 2020, 29(3): 229-232.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2020.03.016 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2020/V29/I3/229

[1] Abraha I,Aristei C,Palumbo I,et al. P reoperativeradiotherapyand curative surgery for the management of localised rectal carcinoma[J]. Cochrane Database Syst Rev,2018,10:CD002102. DOI:10.1002/14651858.
[2] Iorio MV,Croce CM. MicroRNA dysregulation in cancer:diagnostics,monitoring and therapeutics. A comprehensive review[J]. EMBO Mol Med,2012,4(3):143-159. DOI:10.1002/emmm.201100209.
[3] Liang L,Zhu J,Zaorsky NG,et al. MicroRNA-223 enhances radiation sensitivity of U87mg cells in vitro and in vivo by targeting ataxia telangiectasia mutated[J]. Int J Radiat Oncol Biol Phys,2014,88(4):955-960. DOI:10.1016/j.ijrobp.2013.12.036.
[4] Zhang P,Wang L,Rodriguez-Aguayo C,et al.miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13[J]. Nat Commun,2014,5:5671. DOI:10.1038/ncomms6671.
[5] Bandara KV,Michael MZ,Gleadle JM. MicroRNA Biogenesisin Hypoxia[J]. Microrna,2017,6(2):80-96. DOI:10.2174/2211536606666170313114821.
[6] Bu P,Chen KY,Chen JH,et al. A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells[J]. Cell Stem Cell,2013,12(5):602-615. DOI:10.1016/j.stem.2013.03.002.
[7] Zhu Y,Wang C,Becker SA,et al.miR-145 Antagonizes SNAI1-Mediated Stemness and Radiation Resistance in Colorectal Cancer[J]. Mol Ther,2018,26(3):744-754. DOI:10.1016/j.ymthe.2017.12.023.
[8] Kelley KA,Ruhl RA,Rana SR,et al. Understanding and Resetting Radiation Sensitivity in Rectal Cancer[J]. Ann Surg,2017,266(4):610-616. DOI:10.1097/SLA.0000000000002409.
[9] Zheng L,Zhang Y,Liu Y,et al. MiR-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer[J]. J Transl Med,2015,13(2):252. DOI:10.1186/s12967-015-0592-z.
[10] Afshar S,Najafi R,Sedighi-Pashaki A,et al. MiR-185 enhances radiosensitivity of colorectal cancer cells by targeting IGF1R and IGF2[J]. Biomed Pharmacother,2018,106(4):763-769. DOI:10.1016/j.biopha.2018.07.002.
[11] Drebber U,Lay M,Wedemeyer I,et al. Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy[J]. Int J Oncol,2011,39(2):409-415. DOI:10.3892/ijo.2011.1036.
[12] Lopes-Ramos CM,Habr-Gama A,Quevedo Bde S,et al. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients[J]. BMC Med Genomics,2014,7(1):68. DOI:10.1186/s12920-014-0068-7.
[13] Caramés C,Cristobal I,Moreno V,et al. MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer[J]. Int J Colorectal Dis,2015,30(7):899-906. DOI:10.1007/s00384-015-2231-9.
[14] Caramés C,Cristobal I,Moreno V,et al. MicroRNA-31 emerges as a predictive biomarker of pathological response and outcome in locally advanced rectal cancer[J]. Int J Mol Sci,2016,17(6):878-884. DOI:10.3390/ijms17060878.
[15] Svoboda M,Izakovicova-Holla L,Sefr R,et al. Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer[J]. Int J Oncol,2008,33(3):541-547.
[16] D′Angelo E,Fassan M,Maretto I,et al. Serum miR-125b is a non-invasive predictive biomarker of the pre-operative chemoradiotherapy responsiveness in patients with rectal adenocarcinoma[J]. Oncotarget,2016,7(19):28647-28657. DOI:10.18632/oncotarget.8725.
[17] Hiyoshi Y,Akiyoshi T,Inoue R,et al. Serum miR-143 levels predict the pathological response to neoadjuvant chemoradiotherapy in patients with locally advanced rectalcancer[J]. Oncotarget,2017,8(45):79201-17921. DOI:10.18632/oncotarget.16760.
[18] Yu J,Li N,Wang X,et al. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer[J]. Oncotarget,2016,7(39):64233-64243. DOI:10.18632/oncotarget.11649.
[19] Deng J,Lei W,Fu JC,et al. Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro[J]. Biochem Biophys Res Commun,2014,443(3):789-795. DOI:10.1016/j.bbrc.2013.11.064.
[20] Della Vittoria-Scarpati G,Falcetta F,Carlomagno C,et al. A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J]. Int J Radiat Oncol Biol Phys,2012,83(4):1113-1119. DOI:10.1016/j.ijrobp.2011.09.030.
[21] Zhang Y,Yu J,Liu H,et al. Novel epigenetic CREB-miR-630 signaling axis regulates radiosensitivity in colorectal cancer[J/OL]. PLoS One,2015,10(8):e0133870. DOI:10.1371/journal.pone.0133870.
[22] Millino C,Maretto I,Pacchioni B,et al. Gene and microRNA expression are predictive of tumor response in rectal adenocarcinoma patients treated with preoperative chemoradiotherapy[J]. J CellPhysiol,2017,232(2):426-435. DOI:10.1002/jcp.25441.
[23] Ruhl R,Rana S,Kelley K,et al.microRNA-451a regulates colorectal cancer proliferation in response to radiation[J]. BMC Cancer,2018,18(1):517. DOI:10.1186/s12885-018-4370-1.
[24] Hotchi M,Shimada M,Kurita N,et al.microRNA expression is able to predict response to chemoradiotherapy in rectal cancer[J]. Mol Clin Oncol,2013,1(1):137-142. DOI:10.3892/mco.2012.9.
[25] Nakao T,Iwata T,Hotchi M,et al. Prediction of response to preoperative chemoradiotherapy and establishment of individualized therapy in advanced rectal cancer[J]. Oncol Rep,2015,34(4):1961-1967. DOI:10.3892/or.2015.4196.
[26] Ju H,Tan JY,Cao B,et al. Effects of miR-223 on colorectal cancer cell proliferation and apoptosis through regulating FoxO3a/BIM[J]. Eur Rev Med Pharmacol Sci,2018,22(12):3771-3778. DOI:10.26355/eurrev_201806_15259.
[27] Zhu Y,Peng Q,Lin Y,et al. Identification of biomarker microRNAs for predicting the response of colorectal cancer to neoadjuvant chemoradiotherapy based on microRNA regulatory network[J]. Oncotarget,2017,8(2):2233-2248. DOI:10.18632/oncotarget.13659.
[28] Svoboda M,Sana J,Fabian P,et al. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients[J]. Radiat Oncol,2012,7(1):195. DOI:10.1186/1748-717X-7-195.
[29] Kheirelseid EA,Miller N,Chang KH,et al.miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy[J]. Int J Colorectal Dis,2013,28(2):247-260. DOI:10.1007/s00384-012-1549-9.